Estrogens

Breastfeeding
  • TRADE NAMES: Cyren A; Destrol; Estinyl; Estrace (Warner Chilcott); Estraderm (Novartis); Estratab (Solvay); Estroject; Estronol; Estrovis; Gynogen; Menest (Monarch); Ogen (Pfizer); Premarin (Wyeth); Stilphostrol; Theelin
  • INDICATIONS: Menopausal symptoms, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, postmenopausal osteoporosis
  • CLASS: Estrogen
  • HALF-LIFE: N/A

Estrogen administration to women who are breastfeeding has been shown to decrease the quantity and quality of the milk. Estrogens are not indicated for the prevention of postpartum breast engorgement.

A Women's Health Initiative (WHI) estrogen alone study reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50–79 years of age) and an increased risk of developing probable dementia in postmenopausal women over 65 years of age.

Large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children. Estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce gynecomastia.

Our database has 55 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
ENDOCRINE/METABOLIC
GENITOURINARY
OCULAR
LOCAL


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric